Pharmaceutical News and Articles

Conversion Therapy Harms Heart Health

Conversion therapy might harm a young person s long-term heart health, a new study says.Young adults assigned male at birth were nearly three times as likely to

Nicotine Pouch Use Doubles Among U.S. High Schoolers

The use of nicotine pouches nearly doubled among U.S. high school students between 2023 and 2024, a new study says.These pouches, inserted between the gum and l

Food Choices Could Influence First Period, Research Shows

WEDNESDAY, May 7, 2025 What your child eats could play a role in when they start puberty, a new study shows.Researchers found that girls who ate more inflammato

Europe Launches $565 Million Campaign to Attract U.S. Scientists

WEDNESDAY, May 7, 2025 The European Union is looking to capitalize on the Trump administration s dismantling of U.S. research programs to beef up its own.A 565

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA 5 May 2025 Alterity Therapeutics (ASX ATH, NASDAQ ATHE) ( Alterity or the Company ), a biotechnology company dedicat

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

Vanda Announces Bysanti NDA Filing; FDA Decision Expected in Early 2026

No Increase Seen in Risk for Incident Diverticulitis With Nuts, Seeds, Corn Intake

Dietary intake of nuts, seeds, and corn is not associated with an increased risk for incident diverticulitis among women, according to a study published online

Obtaining Second Opinion Delays Treatment for Breast Cancer, but Not Appreciably

For patients with newly diagnosed breast cancer, obtaining a second opinion is associated with increased overall time from diagnosis to treatment however, time

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a poten